Belldegrun Arie 4

What Happened Arie Belldegrun, a director of UroGen Pharma Ltd. (URGN), received a grant of 20,000 derivative shares (a stock option award) on 2026-06-22. The award was reported at $0.00 per share (no cash paid at grant) and thus has $0 cash outlay at issuance. This is a compensation grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-22; Form 4 filed 2026-06-24 (timely filing).
• Security: derivative instrument (stock option) for 20,000 shares; reported price $0.00.
• Total reported cash paid at grant: $0.
• Vesting: the shares underlying the option vest in equal quarterly installments over one year, subject to the director's continuous service (see footnote F1).
• Shares owned after the transaction: not specified in the provided filing summary.
• Transaction type code: A (award/grant).

Context This grant is a standard director compensation award (a stock option), not an exercised option or a market trade. The option vests over four equal quarterly installments across one year; Belldegrun will only acquire the underlying shares as they vest and any exercise conditions are met. Such grants are common for board compensation and do not by themselves indicate buying or selling sentiment.